GlassScriptPhysician profile
Jonathan Siegel
NPI 1639110224
$14,692.72
in general payments reported to CMS, 2019-2025
45 companies · $2,838 in 2025
The $2,838 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,397 · 2020: $781 · 2021: $1,842 · 2022: $2,724 · 2023: $2,278 · 2024: $2,832 · 2025: $2,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,849 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,848.75 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,392.80 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,702.18 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,621.74 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,504.95 | 2019-2025 | Xifaxan, Relistor |
| Ironwood Pharmaceuticals, INC | $636.24 | 2019-2024 | Linzess |
| Celgene Corporation | $566.79 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $497.39 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $455.90 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $420.41 | 2023-2025 | Dupixent |
| Pfizer INC. | $411.43 | 2019-2025 | |
| Lilly USA, LLC | $356.50 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $331.22 | 2019-2025 | Epclusa |
| Madrigal Pharmaceuticals | $266.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $251.90 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $223.24 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $185.63 | 2021-2024 | Suflave |
| Ferring Pharmaceuticals INC. | $173.65 | 2022-2025 | Rebyota, Cimzia, Clenpiq |
| Intercept Pharmaceuticals, INC. | $168.27 | 2019-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $161.17 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $138.26 | 2019-2024 | Dificid |
| Qol Medical, LLC | $133.63 | 2024-2025 | Sucraid, Sucraid |
| Shionogi INC | $130.48 | 2019 | |
| Janssen Scientific Affairs, LLC | $120.47 | 2021 | |
| Amgen INC. | $118.82 | 2021-2023 | Avsola, Amjevita |
| Aimmune Therapeutics, INC. | $111.28 | 2024-2025 | Zenpep |
| Horizon Therapeutics Plc | $111.17 | 2019-2020 | |
| Ucb, INC. | $68.81 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $63.76 | 2025 | Iqirvo |
| Shield Therapeutics INC | $60.58 | 2024 | |
| Medtronic, INC. | $59.83 | 2024 | Interstim |
| Boston Scientific Corporation | $59.20 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $37.99 | 2019 | |
| Celltrion USA INC. | $35.52 | 2025 | Vegzelma |
| Exact Sciences Corporation | $34.88 | 2024 | Cologuard Collection Kit |
| Organon LLC | $18.10 | 2025 | Renflexis, Hadlima |
| Allergan, INC. | $17.92 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $14.89 | 2022 | |
| Alfasigma USA, INC. | $14.75 | 2020 | |
| Redhill Biopharma INC. | $14.25 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.